SG193630A1 - Markers for identifying tumor cells, methods and kit thereof - Google Patents

Markers for identifying tumor cells, methods and kit thereof Download PDF

Info

Publication number
SG193630A1
SG193630A1 SG2013072483A SG2013072483A SG193630A1 SG 193630 A1 SG193630 A1 SG 193630A1 SG 2013072483 A SG2013072483 A SG 2013072483A SG 2013072483 A SG2013072483 A SG 2013072483A SG 193630 A1 SG193630 A1 SG 193630A1
Authority
SG
Singapore
Prior art keywords
cancer
combination
group
cells
prognosis
Prior art date
Application number
SG2013072483A
Other languages
English (en)
Inventor
Manjiri Bakre
Original Assignee
Oncostem Diagnostics Mauritius Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncostem Diagnostics Mauritius Pvt Ltd filed Critical Oncostem Diagnostics Mauritius Pvt Ltd
Publication of SG193630A1 publication Critical patent/SG193630A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
SG2013072483A 2011-03-27 2012-03-26 Markers for identifying tumor cells, methods and kit thereof SG193630A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2835CH2010 2011-03-27
PCT/IB2012/051427 WO2012131564A1 (en) 2011-03-27 2012-03-26 Markers for identifying tumor cells, methods and kit thereof

Publications (1)

Publication Number Publication Date
SG193630A1 true SG193630A1 (en) 2013-10-30

Family

ID=46877646

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013072483A SG193630A1 (en) 2011-03-27 2012-03-26 Markers for identifying tumor cells, methods and kit thereof

Country Status (8)

Country Link
US (2) US8772455B2 (https=)
EP (1) EP2691776A4 (https=)
JP (1) JP2014515821A (https=)
KR (1) KR101621036B1 (https=)
CN (1) CN103562723B (https=)
AU (1) AU2012235767B2 (https=)
SG (1) SG193630A1 (https=)
WO (1) WO2012131564A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9938583B2 (en) 2013-03-15 2018-04-10 Varian Medical Systems, Inc. Biomarkers for radiation treatment
CN105339390A (zh) * 2013-04-29 2016-02-17 Ogd2药物 靶向o-乙酰化的gd2神经节苷脂作为针对癌症干细胞的新型治疗和诊断策略
JP6841609B2 (ja) 2015-07-10 2021-03-10 ３スキャン インコーポレイテッド 組織学的染色の空間的多重化
FR3044680B1 (fr) * 2015-12-02 2017-12-22 Univ Limoges Methode de detection de cellules souches cancereuses
US10900968B2 (en) * 2016-05-24 2021-01-26 Oncostem Pte. Ltd. Method of prognosing and predicting breast cancer recurrence, markers employed therein and kit thereof
CN106053172B (zh) * 2016-06-03 2018-10-30 浙江世纪康大医疗科技股份有限公司 一种edta抗原修复液
US10166406B2 (en) 2017-02-24 2019-01-01 Varian Medical Systems International Ag Radiation treatment planning and delivery using collision free regions
CN115429881A (zh) * 2022-09-02 2022-12-06 中国医学科学院基础医学研究所 铁螯合剂治疗β-连环蛋白活化突变的肿瘤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080601A2 (en) * 2004-02-23 2005-09-01 Erasmus Universiteit Rotterdam Classification, diagnosis and prognosis of acute myeloid leukemia by gene expression profiling
DE602005018789D1 (de) * 2004-08-10 2011-05-26 Cardiff Biolog Ltd Verfahren und kit zur prognose von brustkrebs
WO2007075672A2 (en) * 2005-12-23 2007-07-05 Lankenau Institute For Medical Research Prognostic cancer markers
UA110315C2 (uk) * 2006-09-29 2015-12-25 Oncomed Pharm Inc Композиція та спосіб лікування раку
EA018260B1 (ru) * 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
US7968169B2 (en) * 2007-08-07 2011-06-28 The Boeing Company Compound contoured composite beams and fabrication methods
EP2274617A4 (en) * 2008-04-10 2011-11-09 Massachusetts Inst Technology METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS
WO2011007853A1 (ja) * 2009-07-14 2011-01-20 リンク・ジェノミクス株式会社 癌特異的アイソフォームに対するモノクローナル抗体
WO2011113047A2 (en) * 2010-03-12 2011-09-15 The Johns Hopkins University Compositions and methods for characterizing breast cancer

Also Published As

Publication number Publication date
US8772455B2 (en) 2014-07-08
WO2012131564A1 (en) 2012-10-04
EP2691776A4 (en) 2015-04-15
CN103562723B (zh) 2017-04-26
CN103562723A (zh) 2014-02-05
EP2691776A1 (en) 2014-02-05
AU2012235767A1 (en) 2013-11-07
KR101621036B1 (ko) 2016-05-13
AU2012235767B2 (en) 2016-02-04
US20120244556A1 (en) 2012-09-27
KR20140015500A (ko) 2014-02-06
JP2014515821A (ja) 2014-07-03
US20140295459A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
SG193630A1 (en) Markers for identifying tumor cells, methods and kit thereof
Su et al. Kibra and Merlin activate the Hippo pathway spatially distinct from and independent of expanded
Kong et al. Distinct functions of human cohesin-SA1 and cohesin-SA2 in double-strand break repair
Lee et al. TPR is required for the efficient nuclear export of mRNAs and lncRNAs from short and intron-poor genes
Zhang et al. SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases
US20090081237A1 (en) Prognostic, diagnostic, and cancer therapeutic uses of FANCI and FANCI modulating agents
Eguether et al. Intraflagellar transport is deeply integrated in hedgehog signaling
Kosar et al. The human nucleoporin Tpr protects cells from RNA-mediated replication stress
Langer et al. A novel function of junctional adhesion molecule-C in mediating melanoma cell metastasis
Kleinschmidt et al. Rgnef promotes ovarian tumor progression and confers protection from oxidative stress
Segala et al. Vps11 and Vps18 of Vps-C membrane traffic complexes are E3 ubiquitin ligases and fine-tune signalling
Mazaira et al. Nucleocytoplasmic shuttling of the glucocorticoid receptor is influenced by tetratricopeptide repeat-containing proteins
Patel et al. Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression
Zhao et al. RST1 is a FREE1 suppressor that negatively regulates vacuolar trafficking in Arabidopsis
Jensen et al. Disruption of the extracellular matrix progressively impairs central nervous system vascular maturation downstream of β-catenin signaling
Radu et al. Cajal‐type cells from human mammary gland stroma: phenotype characteristics in cell culture
Bolinger et al. Occludin S471 phosphorylation contributes to epithelial monolayer maturation
Su et al. Inhibition of cyclin D1 enhances sensitivity to radiotherapy and reverses epithelial to mesenchymal transition for esophageal cancer cells
Tischler et al. FLIP (C1orf112)-FIGNL1 complex regulates RAD51 chromatin association to promote viability after replication stress
Christians et al. Characterization of the epithelial membrane protein 3 interaction network reveals a potential functional link to mitogenic signal transduction regulation
van Zon et al. Efflux kinetics and intracellular distribution of daunorubicin are not affected by major vault protein/lung resistance-related protein (vault) expression
Faktorová et al. Functional differentiation of Sec13 paralogues in the euglenozoan protists
Harper et al. RNA Pol II inhibition activates cell death independently from the loss of transcription
Lu et al. Zebrafish TMEM47 is an effective blocker of IFN production during RNA and DNA virus infection
Sun et al. Long noncoding RNA LINC01106 promotes lung adenocarcinoma progression via upregulation of autophagy